Trial · NCT02426125
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival (PFS) | Randomization to Radiological Disease Progression or Death from Any Cause (Up to 18 Months) | The first randomized participants. Censored participants: Ramucirumab + Docetaxel = 58, Placebo + Docetaxel =38. | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Randomization to Date of Death from Any Cause (Up to 31.1 Months) | All randomized participants. Censored participants: Ramucirumab + Docetaxel = 78, Placebo + Docetaxel = 67. | Months | MEDIAN |
| SECONDARY | Percentage of Participants With an Objective Response Rate (ORR) | Randomization to Disease Progression (Up to 29.7 Months) | All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Disease Control Rate (DCR) | Randomization to Disease Progression (Up to 29.7 Months) | All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Duration of Response (DoR) | Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 28.4 Months) | All randomized participants with CR or PR. Participants censored in Ramucirumab + Docetaxel = 12 and in Placebo + Docetaxel = 5. | Months | MEDIAN |
| SECONDARY | Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale | Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months) | All randomized participants. Censored participants: Ramucirumab + Docetaxel = 160, Placebo + Docetaxel = 173. | Months | MEDIAN |
| SECONDARY | Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score | Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months) | All randomized participants with baseline and 30-day follow-up data. | units on a scale | MEAN |
| SECONDARY | Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) | Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months) | All randomized participants with baseline and 30-day follow-up data. | millimeter (mm) | MEAN |
| SECONDARY | Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab | Cycle 1 and Cycle 9, Day 1: Predose, Postdose | All randomized participants who had evaluable PK data. | microgram/milliliter (μg/mL) | GEOMETRIC_MEAN |
| SECONDARY | PK: Minimum Concentration (Cmin) of Ramucirumab | Day 1 of Cycle 2, 3, 5 and 9 (Predose and Postdose) | All randomized participants who had evaluable PK data. | μg/mL | GEOMETRIC_MEAN |
| SECONDARY | Number of Participants With Anti-Ramucirumab Antibodies | 29.7 Months | All randomized participants who received at least one dose of study drug at baseline and post-baseline. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02426125/outcomes